Skip to main content
OpenTrials
Completed

NCT Number: NCT04945031

The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis

A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cannabis Chemically-Induced Disorders Marijuana Abuse Mental Disorders Substance-Related Disorders

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Onrumpha Chuenchom

Thanyaburi, Changwat Pathum Thani, 12110, Thailand

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients ≥ 12 years of age
  • Patients who had been diagnosed as Cannabis-induced psychosis by International statistical Classification of Disease and Related Health problem (ICD-10) on 2016 code F12.5
  • Patients had history of use of cannabis in medical chart
  • Patients had the positive urine screening test of cannabis at the first day of admission

Exclusion criteria

  • Patients had psychosis from organic psychosis, defined by diagnosis by ICD-10 code F09.6
  • Unavailable data for evaluate of outcome especially data of drug use, content of drug use or urine screening test
  • Patients who cancel of medical treatment before 7 day after admission.

Treatment and study plan

cannabis

Other

This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.

Primary outcomes

  1. Pharmacological treatment pattern for cannabis-induced psychosis

    Time frame: 30 days

    Pharmacological treatment pattern for cannabis-induced psychosis during admission

Secondary outcomes

  1. Change of Brief psychiatric rating scale (BPRS) form the first day of admission

    Time frame: Day1, Day 8, Day 15 and Day 22

    A high BPRS score is more severe of symptoms than a lower score

Sponsors and collaborators

Lead sponsor

Mahidol University

Other

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jun 30, 2021
Registry last updated
Jun 30, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.